Logo image of UBM.MI

ULISSE BIOMED SPA (UBM.MI) Stock Fundamental Analysis

BIT:UBM - Euronext Milan - IT0005451213 - Common Stock - Currency: EUR

0.76  -0.01 (-1.3%)

Fundamental Rating

2

UBM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. UBM has a bad profitability rating. Also its financial health evaluation is rather negative. UBM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

UBM had negative earnings in the past year.
In the past year UBM has reported a negative cash flow from operations.
UBM had negative earnings in 4 of the past 5 years.
UBM had a negative operating cash flow in each of the past 5 years.
UBM.MI Yearly Net Income VS EBIT VS OCF VS FCFUBM.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

UBM's Return On Assets of -33.05% is in line compared to the rest of the industry. UBM outperforms 52.11% of its industry peers.
UBM's Return On Equity of -38.06% is in line compared to the rest of the industry. UBM outperforms 59.15% of its industry peers.
Industry RankSector Rank
ROA -33.05%
ROE -38.06%
ROIC N/A
ROA(3y)-16.54%
ROA(5y)-9.05%
ROE(3y)-18.47%
ROE(5y)-9.9%
ROIC(3y)N/A
ROIC(5y)N/A
UBM.MI Yearly ROA, ROE, ROICUBM.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UBM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UBM.MI Yearly Profit, Operating, Gross MarginsUBM.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

UBM does not have a ROIC to compare to the WACC, probably because it is not profitable.
UBM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, UBM has more shares outstanding
The debt/assets ratio for UBM is higher compared to a year ago.
UBM.MI Yearly Shares OutstandingUBM.MI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
UBM.MI Yearly Total Debt VS Total AssetsUBM.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

UBM has an Altman-Z score of 1.35. This is a bad value and indicates that UBM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of UBM (1.35) is better than 64.79% of its industry peers.
UBM has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of UBM (0.01) is better than 80.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.35
ROIC/WACCN/A
WACC8.48%
UBM.MI Yearly LT Debt VS Equity VS FCFUBM.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

UBM has a Current Ratio of 2.66. This indicates that UBM is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.66, UBM perfoms like the industry average, outperforming 59.15% of the companies in the same industry.
UBM has a Quick Ratio of 1.76. This is a normal value and indicates that UBM is financially healthy and should not expect problems in meeting its short term obligations.
UBM's Quick ratio of 1.76 is in line compared to the rest of the industry. UBM outperforms 45.07% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 1.76
UBM.MI Yearly Current Assets VS Current LiabilitesUBM.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

3

3. Growth

3.1 Past

UBM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.69%.
The Revenue has grown by 1620.24% in the past year. This is a very strong growth!
The Revenue has been growing by 135.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-39.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.8%
Revenue 1Y (TTM)1620.24%
Revenue growth 3Y40.55%
Revenue growth 5Y135.06%
Sales Q2Q%1432.73%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UBM.MI Yearly Revenue VS EstimatesUBM.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 200K 400K 600K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UBM. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UBM.MI Price Earnings VS Forward Price EarningsUBM.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UBM.MI Per share dataUBM.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

UBM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ULISSE BIOMED SPA

BIT:UBM (4/23/2025, 7:00:00 PM)

0.76

-0.01 (-1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.65%
Inst Owner ChangeN/A
Ins Owners39.27%
Ins Owner ChangeN/A
Market Cap18.60M
AnalystsN/A
Price Target1 (31.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.34
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 4.72
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.05
BVpS0.97
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.05%
ROE -38.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.54%
ROA(5y)-9.05%
ROE(3y)-18.47%
ROE(5y)-9.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.19%
Cap/Sales 3.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 1.76
Altman-Z 1.35
F-Score4
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)34.12%
Cap/Depr(5y)140.08%
Cap/Sales(3y)106.05%
Cap/Sales(5y)137.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.8%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1620.24%
Revenue growth 3Y40.55%
Revenue growth 5Y135.06%
Sales Q2Q%1432.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-262.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-139.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-153.77%
OCF growth 3YN/A
OCF growth 5YN/A